Centroblastic (CB) and immunoblastic (IB) subtypes of diffuse large B cell lymphomas (DLBCL) have such a different clinical outcome that should be considered as separate entities in the WHO classification of lymphomas. A GISL study

Centroblastic (CB) and immunoblastic (IB) subtypes of diffuse large B cell lymphomas (DLBCL) have such a different clinical outcome that should be considered as separate entities in the WHO classification of lymphomas. A GISL study / Federico, Massimo; Artusi, T; Luminari, Stefano; Brugiatelli, M; Ricciotti, M; Marcheselli, L; Molica, S; Lombardo, M; Angrilli, F; Polimeno, G; Gobbi, P.. - In: ANNALS OF ONCOLOGY. - ISSN 0923-7534. - 16:(2005), pp. 97-97.